Abstract: A method for treating a tumor with at least two bifunctional agents. The bifunctional agents each include a binding domain that specifically binds to stage-specific embryonic antigen 4 (SSEA4) or an SSEA4 analog, and an effector domain selected from a cytokine, a cytotoxic agent, an immunoglobulin Fc domain, anti-CD3, and anti-CD16.

Abstract: A method for treating a tumor by administering an antibody or antibody fragment that binds specifically to stage-specific embryonic antigen 4, and an agent that enhances T cell anti-tumor responses. Also provided is a pharmaceutical composition for treating a tumor. The pharmaceutical composition contains an anti-SSEA4 antibody or antibody fragment, an agent that enhances T cell responses, and a pharmaceutically acceptable excipient.

Abstract: A device and method for detecting the presence of a target analyte in a fluid sample are provided. The device can include an inclined capillary tube for transporting a sample fluid containing a sample and functionalized magnetic beads. The functionalized magnetic beads capture the target analyte from the sample fluid. A well is coupled with the inclined capillary tube for containing a developer solution and for receiving the sample fluid. In at least one embodiment a magnet is movably attached to the inclined capillary tube for attracting the magnetic beads of the sample fluid and moving the magnetic beads into the well. A calorimeter is disposed adjacent to the well for receiving heat output from a reaction caused by an enzyme reaction associated with the captured target analyte in the developer solution thereby allowing detection and quantification of the target analyte.

Abstract: The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.

Abstract: The present invention relates to antigen-binding fragment (Fab) and a Fab-effector fusion protein or polypeptide comprising thereof. The Fab of the present invention specifically binds to serum albumin and thereby has extended in vivo half-life. The Fab of the present invention is characterized by not having cysteine residues that are responsible for the interchain disulfide bond in CH1 domain and C kappa L domain as well. The Fab-effector fusion protein or polypeptide of the present invention can be produced in periplasm of E. coli with high yield, and has increased in vivo half-life. Further, the present invention provides E. coli strain which produces various kinds of Fab-effector fusion proteins or polypeptides, and a pharmaceutical composition comprising the fab-effector fusion proteins or polypeptides.

Abstract: Described herein are compositions and methods relating to LAP-binding agents, including, for example, anti-LAP antibodies, and to their use in methods of treatment of cancer. LAP-binding agents affected both systemic and intra-tumor immunity and were shown effective to treat a broad spectrum of cancer types.

Abstract: Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.

Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.

Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.

Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.

Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.

Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).

Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.

Abstract: The present invention relates novel binding molecules comprising a ubiquitin mutein (Affilin®) and a monoclonal antibody or antibody fragment. The invention refers to bispecific and/or bivalent binding proteins or to a therapeutically or diagnostically active component. The invention further relates to the use of these binding proteins' medicine, preferably for use in the treatment of cancer or autoimmune disorders.

Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Abstract: SIRPabodies comprise an immunoglobulin variable region, which may specifically bind a tumor antigen, viral antigen, etc., fused to a sequence comprising a binding domain of SIRP?. The binding domain of SIRP? comprises at least the N-terminal Ig-like domain of SIRP?, and may further comprise additional SIRP? sequences. The SIRPabodies find use in therapeutic methods that benefit from the combined activity of blocking CD47 activity, and antibody targeting, e.g. in the treatment of cancer, etc. In some specific embodiments, the SIRPabody comprises anti-CD20 activity and a SIRP binding domain; anti-CD99 and a SIRP binding domain; or anti-TIM3 activity and a SIRP ? binding domain.

Abstract: The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.

Abstract: This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

Abstract: A method of detecting the presence of glioblastomas and/or recurrent glioblastomas in a subject in need thereof includes isolating CD14+ cells from a blood sample of the subject and determining the ratio of isolated CD14+ cells expressing low levels of HLA-DR to isolated CD14+ cells expressing VNN2, wherein the subject has increased risk of glioblastomas or recurrent glioblastoma if the ratio of isolated CD14+ cells expressing low levels of HLA-DR to isolated CD14+ cells expressing VNN2 is greater than about 2.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.

Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Abstract: Disclosed are the atomic coordinates of compositions comprising Fc heterodimer proteins in crystalline form derived from high resolution x-ray diffraction. Further disclosed are systems and methods for using all or a portion of these atomic coordinates to identify and design improved Fc heterodimer proteins. Further disclosed are compositions comprising a mixture of (i) a solubilized Fc heterodimer protein and (ii) a mother liquor solution. The mother liquor solution comprises between 2% and 10% (v/v) ethylene glycol, between 10% and 25% (w/v) polyethylene glycol having an average molecular weight of between 2000 Daltons and 10000 Daltons, and between 0.05 M and 0.40 M ammonium iodide. Further disclosed are systems and methods of identifying a mutation which promotes heterodimeric Fc chain pair formation in which structure based modeling is performed to identify a candidate mutation to an Fc chain using all or a portion of the disclosed three-dimensional atomic coordinates.

Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.

Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.

Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.

Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

Abstract: A process for fractionating an esterified cellulose ether comprising groups of the formula —C(O)—R—COOH, wherein R is a divalent hydrocarbon group, comprises the steps of a) blending the esterified cellulose ether comprising groups of the formula —C(O)—R—COOH with an aqueous liquid and setting the temperature of the resulting blend to less than 10° C. to dissolve a portion of the esterified cellulose ether in the aqueous liquid, b) separating the non-dissolved portion of the esterified cellulose ether from the remainder of the blend, and c) recovering or disposing of the esterified cellulose ether that is dissolved in the aqueous liquid.

Abstract: A process for preparing an ester of a cellulose ether comprises the steps of reacting a cellulose ether with a dicarboxylic acid anhydride or with a combination of a dicarboxylic acid anhydride and an aliphatic monocarboxylic acid anhydride, wherein the esterification is conducted i) in the absence of an esterification catalyst or in the presence of no more than 0.1 mole of an esterification catalyst per mole of anhydroglucose units of cellulose ether, and ii) in the presence of an aliphatic carboxylic acid, wherein the molar ratio [aliphatic carboxylic acid/anhydroglucose units of cellulose ether] is up to 12/1.

Abstract: This disclosure is to provide a rubber composition excellent in low loss property and wear resistance without deteriorating the processability. The rubber composition of this disclosure contains a rubber component having a diene-based polymer, a silica, and a glycerin fatty acid ester composition, wherein: the diene-based polymer has 3 or more modified functional groups capable of interacting with the silica merely within a range of ¼ of an entire chain length from a terminal, and has at least one monomer structural unit of a diene-based polymer among the modified functional groups; and the glycerin fatty acid ester composition has a glycerin fatty acid monoester and a glycerin fatty acid diester of C8 to C28 fatty acids, and a content of the glycerin fatty acid ester composition is 0.5 to 15 parts by mass per 100 parts by mass of the rubber component.

Abstract: A process for polymerizing or copolymerizing ethylenically unsaturated monomers in the presence of free-radical polymerization initiators, wherein the polymerization is carried out at temperatures from 100° C. to 350° C. and pressures in the range of from 110 MPa to 500 MPa in a continuously operated polymerization reactor which is controlled by a pressure control valve at the outlet of the polymerization reactor, the process comprising continuously monitoring the pressure within the polymerization reactor, feeding a pressure signal to a controller for controlling the control valve and having the controller altering the opening of the pressure control valve to control the pressure within the polymerization reactor, wherein the controller starts an emergency shutdown program when the pressure control valve closes more than a preset threshold value and the pressure within the polymerization reactor decreases below a preset pressure threshold.

Abstract: The present invention provides a composition kit which is suitably used for more convenient production of a bandpass filter with reduced angle dependence, a laminate and a method for producing the same, and a bandpass filter. The composition kit of the present invention includes a first composition containing a liquid crystal compound having a polymerizable group and a dextrorotatory chiral agent, a second composition containing a liquid crystal compound having a polymerizable group and a levorotatory chiral agent, and a third composition containing a color material.

Abstract: Heterocyclic amido transition metal complexes are disclosed for use in alkene polymerization to produce polyolefins, preferably multimodal polyolefins. The heterocyclic amido transition metal complexes are formed by the chelation of a tridentate dianionic heterocyclic amido ligand to a group 3, 4, or 5 transition metal, where the tridentate ligand coordinates to the metal forming a five-membered ring and an eight-membered ring.

Abstract: The disclosure relates to a method for modifying the rheology of a polymer and a polymeric composition obtained by the method. The composition comprises at least one organic peroxide and water in emulsion form. The polymer may comprise a polyolefin. The method comprises extruding a molten polymer and the composition and removing volatile compounds from the molten polymer.

Abstract: A method for producing a (meth)acrylic resin composition, comprising: continuously feeding reaction starting materials to a tank reactor, the reaction starting materials comprising a polymerizable monomer component, a chain transfer agent and a radical polymerization initiator, the polymerizable monomer component comprising 50 to 100% by mass of methyl methacrylate, 0 to 20% by mass of an acrylic acid alkyl ester and 0 to 30% by mass of an additional monomer; conducting bulk polymerization of the polymerizable monomer component at a polymerization conversion ratio of 40 to 70% by mass to obtain a liquid containing a (meth)acrylic resin; continuously feeding the resulting liquid to a vented extruder to separate volatile component from the (meth)acrylic resin; conducting distillation using an atmospheric distillation column to separate the volatile component into a high boiling fraction (C1) and a low boiling fraction (A1); and conducting distillation using a vacuum distillation column having a pressure of ?50

Abstract: Disclosed are polycationic polymers. The polycationic polymers can include a plurality of positively charged centers, each of which is formed by condensation of cyclic bis-electrophile (e.g., a 9-thia/aza/selenabicyclo[3.3.1]nonyl electrophile) with a nucleophile. The resulting polycationic polymers can efficiently bind nucleic acids. The polycations can also exhibit properties of cytotoxicity and DNA transfection with interesting structure-activity characteristics.

Abstract: Provided are a catalyst composition and a method of oligomerizing olefins using the same. When the catalyst composition according to the present invention is used, oligomerization and copolymerization of olefin monomers may be performed in a single reactor at the same time with high efficiency without a separate process of preparing alpha-olefin. Therefore, costs for preparing or purchasing comonomers which are expensive raw materials may be reduced, thereby reducing the production cost of a final product. Contents of SCB (short chain branch) and LCB (long chain branch) in the polyolefin may be increased without separate feeding of comonomers, thereby producing high-quality linear low-density polyethylene.

Abstract: Phenolate ligands and transition metal complexes are disclosed for use in alkene polymerization, with optional chain transfer agent, to produce polyolefins.

Abstract: The process begins by obtaining a first batch of monomers selected from a group of acrylates with a molecular weight equal to or less than butyl acrylate and/or methacrylate with a molecular weight equal to or less than butyl methacrylate. A second batch of monomers is then selected from a group of acrylates with a molecular weight greater than butyl acrylate and/or methacrylate with a molecular weight greater than butyl methacrylate. A mixture is then prepared by mixing the first batch of monomers and the second batch of monomers, wherein the second batch of monomers are greater than 50% by weight of the mixture. Finally, the mixture is polymerized to produce an ultra high molecular weight polymer.

Abstract: A polymer comprising In this polymer R1 and R4 can be independently selected from the group consisting of H and alkyl groups; R2 and R3 can be independently selected from the group consisting of H, alkyl, olefinic, aromatic, heterocyclic, halogen, ammonium, nitroxides, nitrates, nitrite amides, amines, esters, ethers, carboxylic acids, acyl chlorides, alcohols, nitriles, phosphates, phosphonates, sulfates, sulfonates, sulfide, sulfite, thiol, and combinations thereof; Y can be selected from the group consisting of O, N and S; Z can be a hydrogen bonding group that is at least triple bonded or higher and X are methylene groups.

Abstract: A polymer comprising

Abstract: A method of forming a thermoresponsive polymer. The method proceeds by mixing 2-(3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)ureido)ethyl methacrylate and methacrylamide in the presence of a solvent form a monomer solution. An initiator is then added to the monomer solution to form a thermoresponsive polymer.

Abstract: A method of forming a thermoresponsive polymer. The method begins by mixing in the presence of an organic solvent to form a monomer solution. An initiator is then added to the monomer solution to form a thermoresponsive polymer. In this method, R1 and R4 can be independently selected from the group consisting of H and alkyl groups; R2 and R3 can be independently selected from the group consisting of H, alkyl, olefinic, aromatic, heterocyclic, halogen, ammonium, nitroxides, nitrates, nitrite amides, amines, esters, ethers, carboxylic acids, acyl chlorides, alcohols, nitriles, phosphates, phosphonates, sulfates, sulfonates, sulfide, sulfite, thiol, and combinations thereof; Y can be selected from the group consisting of O, N and S; R5 and R6 can be independently selected from the group consisting of alkyl, olefinic, heterocyclic, halogens, ammonium, carboxylic, amines, esters, amides and combinations thereof; and X are methylene groups from about 0 to about 20 carbons.